

## 。 GDAŃSK UNIVERSITY OF TECHNOLOGY

## Subject card

Subject name and code	Smart Biopharmaceuticals, PG_00058280								
Field of study	Biotechnology								
Date of commencement of studies	February 2024		Academic year of realisation of subject			2024/2025			
Education level	second-cycle studies		Subject group			Optional subject group Subject group related to scientific research in the field of study			
Mode of study	Full-time studies		Mode of delivery			at the university			
Year of study	1		Language of instruction			Polish			
Semester of study	2		ECTS credits			2.0			
Learning profile	general academic profile		Assessment form			assessment			
Conducting unit	Department of Pharm	aceutical Tech	I Technology and Biochemistry -> Faculty of Chemistry						
Name and surname	Subject supervisor	upervisor prof. dr hab. inż. Sławomir M		lilewski					
of lecturer (lecturers)	Teachers								
Lesson types and methods of instruction	Lesson type	Lecture	Tutorial	Laboratory	Projec	t	Seminar	SUM	
	Number of study hours	15.0	0.0	0.0 0.0			15.0	30	
	E-learning hours included: 0.0								
Learning activity and number of study hours	Learning activity	Participation in classes includ plan	n didactic ed in study	Participation in consultation hours		Self-study		SUM	
	Number of study hours	30		2.0		18.0		50	
Subject objectives	This course is a source of knowledge on modern second generation biopharmaceuticals exhibiting high selectivity due to the presence of fragments responsible for the targeted action of an active component.								
Learning outcomes	Course outcome		Subject outcome		Method of verification				
	[K7_W06] has knowledge about modern forms of drugs, including drugs of plant origin, new generation vaccines, alternative forms of therapy based on phages, knows issues related to biological activity of plant chemicals, knows how to test new drugs and how to introduce them to the market		The student is able to give examples of second-generation biopharmaceuticals and explain the molecular basis of their targeted biological action.			[SW3] Assessment of knowledge contained in written work and projects [SW1] Assessment of factual knowledge			
	[K7_U10] is able to use knowledge about possibilities, aims and limitations of biotechnology to develop, design and obtain products and biotechnological processes in the area of his/her specialization [K7_K02] is aware of the limitations and the pecessity of		The student has acquired knowledge at an advanced level regarding the possibilities of designing structures of second- generation biopharmautics and their production using biotechnological methods. Students, working in groups, analyze the state of knowledge			[SU4] Assessment of ability to use methods and tools [SU3] Assessment of ability to use knowledge gained from the subject [SK2] Assessment of progress of work			
	continuous development of knowledge and technology; understands the need for education and constant training		analyze the state of knowledge about specific biopharmaceuticals and present the result of this analysis in a synthetic way.			[SK1] Assessment of group work skills			
	[K7_U04] is able to predict potential properties of biomolecules and biologically active compounds on the basis of knowledge of their chemical structure and apply methods of molecular modelling of biomolecules		<ol> <li>Student is able to identify structural features of a given biopharmaceutic conditioning its biological properties.</li> <li>Student indicates alternative posibilities of modification of structure of a given biopharamaceutic towards changing a particular biological property.</li> </ol>			[SU2] Assessment of ability to analyse information [SU3] Assessment of ability to use knowledge gained from the subject			

Subject contents	1. Drug targeting - strategies and ways of execution							
	2. Strategies of improvement of properties, including selective toxicity of antimicrobials and anticancer drugs							
	3. Mechanisms of microbial drug resistance and strategies of its overcoming							
	<ol> <li>4. Drug carriers - classes and applications</li> <li>5. Strategies of construction of drug conjugates</li> </ol>							
	<ul> <li>6. Modern methods of construction and modification of proteinous biopharmaceuticals</li> <li>7. Design and preparation of drugs based on antibodies and antibody fragments</li> <li>8. Medicinal preparations based on DNA and mRNA</li> </ul>							
Prerequisites and co-requisites	Basic knowledge on low molecular weight, proteinous and nucleic acids-based biopharmaceuticals gained during first-cycle studies.							
Assessment methods and criteria	Subject passing criteria	Passing threshold	Percentage of the final grade					
	Written tests on lecture materials	50.0%	60.0%					
	assessment of own presentation and activity during seminars	50.0%	40.0%					
Recommended reading	Basic literature D.J.A. Crommelin, R.D. Sindelar, B. Meibohm (eds). Pharmaceutical Biotechnology. Fundamentals and Applications. Fifth edition, Springer, New York, 2019							
	Supplementary literature	R.J.Y Ho and M. Gibaldi (eds.) Biotechnology and Biopharmaceuticals, John Wiley & Sons Inc., Hoboken, 2003						
	eResources addresses	Adresy na platformie eNauczanie:						
Example issues/ example questions/ tasks being completed	1. Drug targeting - examples							
	2. Structural modifications of antimicrobial drugs - goals and ways to achieve them							
	3. Classes of drug carriers							
	4. Linkers used in construction of drug conjugates							
	5. Techniques of preparation drug:antibody conjugates							
	6. Modifications of oligonucleotides aimed at their protection against nucleases							
Work placement	Not applicable	Not applicable						